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Nasal carriage of Staphylococcus aureus represents a well-defined factor of risk
involving community and hospital-acquired infections. Recently a significance of several
host factors has been pointed out and, in particular, of immune determinants in nasal
S. aureus colonization. Therefore, this study aimed at analysis of manifestation involving
manifestation in the nasal secretions of important components of the host innate
immunity – human beta-defensin-2 (HBD-2), lysozyme (Ly), and interferon-gamma
(IFN-γ) in healthy individuals and in persons with persistent carriage of S. aureus. The
studies were conducted in two groups of healthy volunteers, encompassing non-carriers
(group 1) or persistent carriers of S. aureus (group 2). Elisa assays were employed to
evaluate levels of HBD-2, Ly, and IFN-γ in nasal secretions of the examined donors. In
S. aureus carriers a significant variability of HBD-2 levels was detected, corresponding
to, respectively, the high (averaging at 1.46 ng/ml) and the low (averaging at 0.13 ng/ml)
secretory response of the defensin. The level of Ly in S. aureus carriers averaged at
1.46 µg/ml and it manifested no significant difference as compared to that noted in
non-carriers. In turn, concentrations of IFN-γ in nasal secretions in the group of carriers
of S. aureus amounted on the average to 81.7 pg/ml and they were 1.3-fold higher that
in the group of non-carriers. The obtained results allow to conclude that IFN-γ secretion
by the nasal cavity-colonizing S. aureus remains quantitatively insufficient to eliminate
the pathogen. Nevertheless, a significant increase in levels of this host factor may
be important for restriction of the staphylococcal colonization and protection against
development of an invasive infection. In turn, the role of HBD-2 and Ly in inactivation of
the colonizing S. aureus remains doubtful.
Keywords: Staphylococcus aureus, nasal carriage, human beta-defensin-2 (HBD-2), lysozyme (Ly), interferon-
gamma (IFN-γ)
INTRODUCTION
Staphylococcus aureus represents one of the most frequently occurring community and hospital-
acquired pathogens (Wertheim et al., 2004; Verhoeven et al., 2014). The vestibulum nasi is the
primary reservoir of S. aureus in humans, and nasal carriage has been related to an increased
risk of staphylococcal disease (Wertheim et al., 2005; Verhoeven et al., 2014). The nasal strains
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S. aureus originating from carriers were demonstrated also to
carry toxin genes, most frequently the gene coding for toxic
shock syndrome toxin 1 (TSST-1) – tst (Mehrotra et al., 2000).
Moreover, persistent carriers exhibited higher than in non-
carriers serum anti-staphylococcal antibodies targeted at TSST-1
(Verkaik et al., 2009). At present, two categories of nasal carriers
are distinguished, involving persistent and non-persistent carries,
respectively (Van Belkum et al., 2009). The persistent nasal
carriage of S. aureus is appraised to affect around 20–30% of
the whole population, in Poland on the average 28% of healthy
adults (Wertheim et al., 2005; Chudzicka-Strugała et al., 2015).
In the process of S. aureus nasal colonization various bacterial
factors play role, mainly adhesion molecules such as surface
components, including clumping factor B (ClfB) and cell wall
teichoic acids (Mulcahy et al., 2012; Weidenmaier et al., 2012).
Nevertheless, genetic investigations indicate that there exists no
specific bacterial factor linked to persistent nasal carriage of
S. aureus (Lamers et al., 2011). However, a significance of certain
bacterial species in the normal flora was pointed out for reduction
of S. aureus nasal colonization (Frank et al., 2010). In parallel,
involvement of host innate immunity, in particular of defensins
and of the already well known antibacterial peptides was accepted
in reduction of S. aureus nasal carriage (Van Belkum et al., 2007;
Sollid et al., 2014). Nevertheless, the role of this defensin and
of the other important determinants of innate immunity still
remains unclear in the nasal S. aureus colonization.
Therefore, this study aimed at analysis of the presence in the
nasal secretions of human beta-defensin-2 (HBD-2), lysozyme
(Ly), and interferon-gamma (IFN-γ) in healthy individuals and
in persons with persistent nasal carriage of S. aureus.
MATERIALS AND METHODS
Patients
The studies were performed in the Department of Medical
Microbiology, Poznan´ University of Medical Sciences, over a
period of 2 years (2014–2015). All the research protocols were
reviewed and approved by the Ethics Committee at the Poznan´
University of Medical Sciences, Poland. All subjects gave written
informed consent in accordance with the Declaration of Helsinki.
Sixty persons were qualified for the studies, in two research
groups. The first group (group 1) included 30 persons (20
womens and 10 mens), 19–24 years of age, classified as non-
carriers of S. aureus. Group 2 comprised 30 persons (18 womens
and 12 mens), 20–24 years of age, confirmed persistent S. aureus
nasal carriers. For the carriers, nasal cultures were positive
for S. aureus on two occasions during a minimum interval of
3 months, according to Panierakis et al. (2009). The volunteers
did not include health care workers. The investigated groups
included no individuals with current infection or reporting
chronic diseases or persons reporting in anamnesis genetic
diseases. Moreover, persons with anatomic alterations in the nose,
smokers, individuals administered with oral contraceptives and
i.v., drug users were excluded. Within the previous 2 weeks,
none of the patients in the mentioned groups was administered
with antibiotics/chemotherapeutic agents locally or systemically.
Additionally, dental examinations of patients failed to find any
potential infection foci in the oral cavity. The investigated
material involved nasal swab samples for detection of bacterial
carriage and nasal secretions for estimation of levels of HBD-2,
Ly, and IFN-γ. Nasal secretions were collected by vacuum-aided
suction without chemical stimulation, as earlier described (Cole
et al., 1999). Gentle manipulation of a rubber-tipped vacuum
device inside the nasal passageways stimulated release of nasal
fluid. Nasal secretions were stored at –20◦C until further analyses
were performed.
Detection of S. aureus
The bacteria were isolated on sheep blood agar within
20–24 h at a temperature of 37◦C in aerobic conditions.
The developed colonies were subsequently identified using
conventional techniques (colony morphology, evaluation of
haemolysis, staining according to Gram, production of coagulase,
catalase, ability to decompose mannitol in Chapman medium).
Identification of S. aureus was conducted using the automated
system ATB with the application of ID 32 Staph strips
(bioMérieux). Moreover, presence of S. aureus was confirmed
using PCR. All strains of S. aureus proved to be methicillin-
sensitive (MSSA).
Detection of S. aureus using PCR
DNA was isolated from the obtained isolates of S. aureus clinical
strains. At first, the samples were digested with lysostaphin
(10 µl of 1 mg/ml solution) and incubating them for 10 min
at a temperature of 37◦C. Subsequently, for the isolation
of DNA, Swab kits (A&A Biotechnology) were used. The
isolation of DNA was conducted as recommended by the
manufacturer. The purified DNA was stored at –20◦C until
further analyses were performed. In PCR studies the following
oligonucleotide primers were used according to Martín-López
et al. (2004): femB1 5′-TTACAGAGTTAACTGTTACC-3′ and
femB2 5′-ATACAAATCCAGCACGCTCT-3′ from femB gene of
S. aureus. PCR reaction was conducted in 25 µl of mixture
consisting of 1x reaction buffer [10 mM Tris-HCl (pH 8.3)],
2.5 mM MgCl2, 0.2 mM of each of the four dNTPs, 1.25 U of Taq
DNA polymerase, 0.2 µM of each primer and 1 µl of templete
DNA. The PCR reaction was conducted in the Mastercycler Pro
S thermocycler (Eppendorf) with the following thermal cycling
profile: an initial denaturation at 94◦C for 4 min, denaturation at
94◦C for 45 s, annealing at 50◦C for 45 s, and extension at 72◦C
for 60 s, ending with a final extension step at 72◦C for 10 min. The
number of cycles in PCR reaction was 30. The PCR product was
subjected to electrophoresis in 1% agarose gel and the result was
recorded following staining with ethidine bromide. A positive
result was accepted to involve presence of PCR reaction product
of 651 bp in size.
Elisa Tests
Levels of HBD-2, Ly, and IFN-γ in nasal secretions were
estimated by Elisa technique using kits of Human Beta Defensin
2 (Alpha Diagnostic), Lysozyme Elisa Kit (Sigma), and Human
IFN-γ High Sensitivity Elisa (eBioscience). Sensitivity of the
applied tests amounted to 5 pg/ml, 0.021 ng/ml and 0.06 pg/ml,
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respectively. The tests were performed as recommended by the
manufacturers. Values of absorbance, depending on the estimated
substance, were read using Reader 250 (bioMérieux). The results
were obtained from standard curves. Every test was performed
three times and the presented result involved mean of the
estimations.
Data Analysis
Results obtained in the studies were subjected to statistical
analysis employing the computer Statistica 8 software for
the Windows operational system. In comparative analysis of
studied factors in the groups, the nonparametric test of Mann–
Whitney and Kruskal–Wallis with Dunn’s was employed. The
relationships with P-values higher than 0.05 were considered
insignificant.
RESULTS
In the group 1 of healthy volunteers (non-carriers S. aureus)
in 26 (87%) persons mean level of HBD-2 amounted to
68.42 ± 18.06 pg/ml, while in 4 (13%) persons the level was
significantly elevated, amounting to 1352.75 ± 206.47 pg/ml. In
group 2 two categories of results were obtained: in 22 (73%)
carriers of S. aureus the mean level of HBD-2 was very high
and it amounted to 1456.23 ± 202.68 pg/ml, while in 8 (27%)
persons concentrations of the defensin were low, averaging at
132.13 ± 15.82 pg/ml. In parallel, the results proved to be
statistically higher than those detected in 87% non-carriers. The
obtained results were summed up in Table 1 and, graphically, in
Figure 1.
In group 1 of healthy volunteers (non-carriers S. aureus)
the mean level of Ly amounted to 1.46 ± 0.34 µg/ml, while
in group 2 of S. aureus carriers the mean level amounted to
1.29 ± 0.30 µg/ml. Levels of the enzyme showed no significant
inter-group difference; they were presented in Table 2 and in
Figure 2.
In group 1 of healthy volunteers (non-carriers of S. aureus) the
mean level of IFN-γ was 63.8 ± 14.2 pg/ml, while in the group
2 of S. aureus carriers it amounted to 81.7 ± 14.8 pg/ml. In the
latter group levels of IFN-γ proved to be significantly higher than
those in group 1 of non-carriers. The results were summed up in
Table 2 and in Figure 3.
TABLE 1 | Levels of HBD-2 in the nasal secretions in non-carriers
Staphylococcus aureus (group 1) and in carriers of S. aureus (group 2).
Studied defensin Mean values ± SD
(minimun–maximum)
P between
groups
group 1
n = 30
group 2
n = 30
HBD-2 (pg/ml) n = 26
68.42 ± 18.06
(32.2–103.8)
n = 8
132.13 ± 15.82
(108.7–156.4)
<0.0001
n = 4
1352.75± 206.47
(1131–1587)
n = 22
1456.23± 202.68
(1121–1775)
>0.05
FIGURE 1 | Graphic presentation of detected levels of HBD-2 in the
nasal secretions in non-carriers Staphylococcus aureus (group 1) and
in carriers of S. aureus (group 2).
DISCUSSION
Several host factors which spontaneously exert anti-microbial
activity create innate immunity against infections (Boman, 2000;
Brown et al., 2014). In this study we conducted investigations
related to presence of three important determinants of innate
immunity, HBD-2, Ly, and IFN-γ in nasal fluids of healthy
persistent carriers of S. aureus and in non-carriers.
HBD-2 involves an antimicrobial peptide, produced mainly by
skin keratinocytes and respiratory epithelial cells in response to
infection and inflammation (Schneider et al., 2005). Currently,
the peptide is thought to form the first line of local defense
at the mucosal surface (Guaní-Guerra et al., 2010). In analysis
of HBD-2 manifestation in nasal fluids originating from the
examined volunteers we obtained two categories of results both
in the group of carriers of S. aureus, and among non-carriers.
In the latter, in around 87% individuals we detected low levels
of the defensin, not exceeding 0.1 ng/ml, while in around 13%
volunteers level of the peptide in nasal fluids was high, exceeding
1 ng/ml. The high levels of HBD-2 were detected also in around
73% carriers of S. aureus. On the other hand, in around 27%
of the remaining carriers levels of the defensin remained within
low concentrations even if they were significantly higher than
those detected in 87% non-carriers. The data correspond with
TABLE 2 | Levels of Ly and IFN-γ in the nasal secretions in non-carriers
S. aureus (group 1) and in carriers of S. aureus (group 2).
Studied factor Mean values ± SD
(minimum–maximim)
P between
groups
group 1
n = 30
group 2
n = 30
Ly (µg/ml) 1.29 ± 0.30
(0.72–1.94)
1.46 ± 0.34
(0.88–2.12)
>0.05
IFN-γ (pg/ml) 63.8 ± 14.2
(42.3–97.6)
81.7 ± 14.8
(50.7–112.2)
<0.0001
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FIGURE 2 | Graphic presentation of detected levels of Ly in the nasal
secretions in non-carriers S. aureus (group 1) and in carriers of
S. aureus (group 2).
those obtained by Cole et al. (2001), who documented high
concentrations of HBD-2 in nasal fluids of persistently colonized
carriers. However, the quoted authors failed to provide the
number of donors in whose nasal fluids the peptide was analyzed
and the employed by them ELISA test showed low sensitivity
(0.125 ng/ml). Therefore, results of their paper can only partially
be compared to our results. The detected by us in persistent
FIGURE 3 | Graphic presentation of detected levels of IFN-γ in the
nasal secretions in non-carriers S. aureus (group 1) and in carriers of
S. aureus (group 2).
S. aureus carriers significant variability in levels of HBD-2, may
represent a result of the presence among healthy individuals
of “high responders” and “low responders,” depending on the
level of induction involving expression of HBD-2 genes in nasal
epithelial cells. Such a conclusion seems to be probable in view
of results obtained by Nurjadi et al. (2013), who demonstrated
associations between genetic polymorphisms, β-defensin (HBD-
1 and HBD-3) expression, and persistent S. aureus nasal carriage.
A suppressive effect is also possible, exerted in the carriers by
S. aureus strains on expression of the defensin, as suggested by
Quinn and Cole (2007). The presented data allow to assume
that the action of HBD-2 against the colonizing S. aureus
remains ineffective. In contrast to this suggestion seem to argue
studies of Routsias et al. (2010), who demonstrated in vitro
high bactericidal efficacy of the defensin against S. aureus
clinical strains. Significance of the studies, however, was reduced
by interpretation because the quoted authors used in their
experiments HBD-2 concentrations significantly higher than the
defensin levels detected by us in the nasal fluids. Moreover,
studies on healthy skin specimens originating from patients
with persistent nasal carriage of S. aureus and from non-
carriers, conducted by Zanger et al. (2011) indicated that nasal
colonization by the pathogen was promoted by a deficit in HBD-
3. Thus, the significantly elevated concentrations of HBD-2 in
nasal secretions of carriers may represent just a sequel of local
inflammatory response against colonizing S. aureus. In turn, the
high levels of the defensin detected in this study in some non-
carriers may reflect its induction by transient nasal microflora,
and the Gram-negative bacilli in particular. Stimulation of HBD-
2 expression by bacterial LPS is already well known (Guaní-
Guerra et al., 2010).
Lysozyme represents a polypeptide manifesting enzymatic
activity (muramidase activity), hydrolysing β-1,4 glycosidic
bonds between N-acetylmuramic acid and N-acetylglucosamine
of bacterial peptidoglycan (Dziarski, 2004). The enzyme creates
an important component of the host innate immunity.
It is present ubiquitously in various human tissues and
secretions, exhibiting antimicrobial activities against different
microorganisms (Dumoulin et al., 2007). Ly was first reported
in nasal secretions by Fleming (1922). In our study we have
found that nasal fluids of healthy donors contain Ly levels
within the range of 0.7–1.9 µg/ml, manifesting no significant
difference as compared to nasal fluids in carriers of S. aureus.
It is difficult to compare the results to those obtained in earlier
studies (Raphael et al., 1989; Noble, 2002), the authors of
which estimated Ly activity using a turbidimetric assay, based
on the enzymatic hydrolysis of bacterial cell walls. Therefore,
the obtained data allow to conclude that Ly does not prevent
against nasal carriage of S. aureus. The conclusion is supported
by studies pointing to high resistance of peptidoglycan of
S. aureus to lytic activity of Ly (Pushkaran et al., 2015).
However, a non-lytic mechanism of the enzyme activity is
also known, related to its cationic and hydrophobic properties,
which results in bacterial autolysis (Masschalck et al., 2002).
Chen et al. (2005) in their in vitro analysis of Ly action
demonstrated its antibacterial activity toward S. aureus and,
moreover, demonstrated a synergism of Ly and HBD-2 actions.
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However, the phenomenon manifested statistically significant
effects only in an acidic milieu (pH 4.6), while nasal fluids
manifest a neutral or slightly alkaline pH (Lee et al., 2009). In the
context of the data it can be concluded that Ly concentrations in
nasal fluid are not sufficient to secure effective elimination of the
colonizing S. aureus.
IFN-γ represents a typical cytokine, produced mainly by
lymphocytes T and NK (Young and Hardy, 1995). The cytokine
plays a central role in the innate immunity to infection. It
also exerts a strong monocyte/macrophage-stimulating effect,
activating phagocytosis and mechanisms for intracellular killing
of pathogens (Schroder et al., 2004). In this study, using high
sensitivity Elisa test for the first time we have documented
IFN-γ estimations in nasal fluids in carriers of S. aureus. The
detected by us levels of the cytokine proved to be comparable
to results recently obtained by König et al. (2015), using a
commercial immunofluorescence multiplexed assay. Also, the
concentrations of IFN-γ detected in nasal secretions of S. aureus
carriers were on the average 1.3-fold higher that those present
in non-carriers. The results correspond to those obtained in the
recently published studies of Brown et al. (2015) on a mouse
in vitro model and in vitro human estimations which showed
that S. aureus enhanced IFN-γ response, which might be followed
by an augmented microbicidal activity of phagocytes and by
elimination of the pathogens. In this context, persistence of
S. aureus carriage may be linked to an insufficient increase of
IFN-γ level to clear the colonizing pathogen. Moreover, a defect
in phagocyte function is also possible, even if in anamnesis
the examined individuals provided no respective indications.
However, the elevated level of IFN-γ may at least in part
mediate a microbicidal activity, preventing against spread of the
infection.
CONCLUSION
The presented data indicate that the detected by us induction
of IFN-γ secretion by nasal cavity-colonizing S. aureus
remained quantitatively insufficient to eliminate the pathogen.
Nevertheless, the significant increase in the host factors may
be of importance for a reduced staphylococcal colonization and
protection against spread of the invasive infection. On the other
hand, involvement of HBD-2 and Ly in inactivation of the
colonizing S. aureus seems doubtful.
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